Oura to acquire Counsel Health for $625 million, placing a big bet on AI care

Oura Health is acquiring Counsel Health for $625 million, aiming to integrate AI and wearable data into clinical care. The deal follows a partnership where Counsel's AI chatbot was added to Oura's app. Oura reported $533 million in revenue for Q3 and $1.75 billion for fiscal 2026, up 92% YoY. Both companies plan to continue their direct-to-consumer and enterprise services post-acquisition.

Original reporting
Published Nov 10, 2026, 11:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 1:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Oura to acquire Counsel Health for $625 million, placing a big bet on AI care — source image
Decision brief

The 30-second read

Low
01

Why it matters

The deal expands Oura's move from consumer data to reimbursable clinical care, creating a new revenue stream but also raising integration and regulatory questions.

02

Market read

First‑report of a sizable private‑company acquisition in the digital‑health space; may influence valuations of similar startups.

03

What to watch

potential conflict of interest with Eli Lilly's minority stake in Oura

Relevance 8/10Novelty 8/10Timing: expected close in December

Background

Oura, a maker of smart rings, announced a $625 million acquisition of private telehealth firm Counsel Health to embed AI‑driven clinical services.

Market effects

could spur further M&A activity in digital health and AI‑enabled wearables

may boost investor interest in Nordic health‑tech startups

limited to health‑tech and AI sectors

Counterpoint

integration risk and regulatory scrutiny could outweigh synergies

Key entities

  • Oura

    Finnish wearable‑tech firm acquiring Counsel Health

  • Counsel Health

    Boston‑based telehealth provider with AI chatbot

Related articles

$LLYMed

HHS, Eli Lilly, Oura, basal ganglia: Readout Newsletter

Eli Lilly's partnership with Counsel Health for GLP-1 prescriptions may be affected by Oura's acquisition of Counsel. Lilly could gain a financial stake in Oura, with a $50 million stock purchase contingent on certain conditions, though these have not yet been met, according to STAT's Elaine Chen.

LowAI 8/10

Oura Is Paying $625 Million to Put a Doctor Behind Its Smart Ring

Oura Health agreed to acquire Counsel Health for $625 million in cash, representing 36% of Oura's last fiscal year's revenue. Counsel provides AI-driven medical chat with licensed doctors, enhancing Oura's smart ring capabilities. The deal is expected to close by the end of 2026, subject to conditions. Oura aims to integrate Counsel's services to offer more comprehensive health solutions, potentially boosting membership retention and IPO prospects.

LowAI 9/10

Oura makes bet on AI in healthcare with $625M Counsel Health buy

Oura plans to acquire AI-based healthcare company Counsel Health for $625M in cash. Counsel's platform combines AI chatbots with human physicians for symptom assessment. Oura aims to integrate the service with its smart ring biometric data. The deal is expected to close by year-end, subject to conditions. Oura delayed its IPO in September due to market uncertainty.

$SIE.DEHighAI 9/10

Tech M&A deals: Entegris, Siemens to Acquire Lauterbach, Oura, Counsel Health

Entegris acquired Advanced Abrasives to expand semiconductor materials for AI chips, investing in Taiwan manufacturing. Siemens agreed to buy Lauterbach for $1.6B to bolster semiconductor design and verification. Oura will acquire Counsel Health for $625M to combine biometric data with AI-powered medical care. Cribl acquired Tero to enhance AI observability and monitoring capabilities.

Low

Oura’s $2.2bn IPO Was Postponed. Where Was the Money Going?

Oura, a smart-ring maker, postponed its $2.2bn IPO on 29 September 2026 due to market uncertainty. The offering included 50 million shares priced between $40 and $44, with most proceeds going to existing investors. Oura planned to use its share for employee tax obligations. The company reported strong revenue growth and profitability but faces market and legal risks. No new IPO date has been set.